Über die Autorinnen und Autoren

Zoran Rankovic is a Senior Research Fellow and a Head of Medicinal Chemistry section at MSD, Merck Research Laboratories, U.K. 15 years experience in drug discovery with a track record of delivering compounds into the development for a number of therapeutic areas, including psychiatry. Over a decade of a direct involvement in shaping the early discovery portfolio for the neuroscience franchise. Zoran has a PhD in organic chemistry from the University of Leeds, UK. Richard Hargreaves is Vice President and Worldwide Head of Neuroscience Discovery Research at Merck - completed his doctorate through the Physiology Department at King's College London University UK. Joined Merck's Neuroscience Research Center in Harlow UK in 1988. Leader of the discovery biology teams that contributed to the development of MAXALT(R) (rizatriptan) for the treatment of migraine and EMEND(R) (aprepitant) and IVEMEND(R) (fosaprepitant), novel agents that advance the protective pharmacotherapy of acute and delayed chemotherapy-induced nausea and vomiting and post-operative nausea and vomiting. In 1999 he became Vice President Worldwide Head of Imaging with the assignment to establish and lead a worldwide imaging research strategy for Merck Research Laboratories. Matilda Bingham is currently Team Leader in the Medicinal Chemistry Department, MSD; 8 years research experience in neuroscience research in a pharmaceutical setting, participating and leading teams in the neuroscience area, specialising in the transporter and GPCR target classes.

Von der hinteren Coverseite

The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there are still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research in drug discovery. The editors have combined their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism. Written by leading experts from industry and academia the book will be essential reading for medicinal chemists, pharmacologists, and pharmaceutical scientists working in psychiatric diorders drug discovery and development.

Aus dem Klappentext

The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there are still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research in drug discovery. The editors have combined their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism. Written by leading experts from industry and academia the book will be essential reading for medicinal chemists, pharmacologists, and pharmaceutical scientists working in psychiatric diorders drug discovery and development.

Auszug. © Genehmigter Nachdruck. Alle Rechte vorbehalten.

Drug Discovery for Psychiatric Disorders

The Royal Society of Chemistry

Contents

Chapter 1 Psychiatric Disorders – an Overview Kathryn M. Connor and David Michelson, 1, 
Section 1: Schizophrenia, 
Chapter 2 The Pathophysiology of Schizophrenia Armin Szegedi and Michael Egan, 13, 
Chapter 3 Monoaminergic Approaches for Treatment of Schizophrenia David P. Rotella, 35, 
Chapter 4 Glutamatergic Approaches for the Treatment of Schizophrenia John A. Morrow, Robert Gilfillan and Stuart A. Neale, 56, 
Chapter 5 Discovery and Clinical Data for a Novel AMPA Receptor Positive Modulator Simon E. Ward, 99, 
Chapter 6 Treating the Cognitive Deficits of Schizophrenia Bruce N. Rogers and David L. Gray, 123, 
Section 2: Depression and Anxiety, 
Chapter 7 The Neurobiology of Depression and Anxiety: How Do We Change from Models of Drug Efficacy to Understanding Mood and Anxiety Disorders? Georgia E. Hodes and Scott J. Russo, 159, 
Chapter 8 Beyond SSRIs: Second-generation Reuptake Inhibitors for the Treatment of Depression Peter T. Gallagher, 184, 
Chapter 9 Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder James W. Murrough, Daniela Schiller and Dennis S. Charney, 226, 
Chapter 10 Glutamate Approaches Towards the Treatment of Mood Disorders Carrie K. Jones, P. Jeffrey Conn and Craig W. Lindsley, 258, 
Chapter 11 Modulation of HPA Axis Function for Treatment of Mood Disorders Shaun P. Brothers, Claes Wahlestedt and Charles B. Nemero, 276, 
Chapter 12 Neuropeptide Receptors: Novel Therapeutic Targets for Depression and Anxiety Disorders Shigeyuki Chaki and Kosuke Kanuma, 300, 
Section 3: Other Psychiatric Disorders, 
Chapter 13 Therapeutic Approaches to Bipolar Disorder Moghis U. Ahmad, Shoukath M. Ali, Saifuddin Sheikh, Ateeq Ahmad and Imran Ahmad, 333, 
Chapter 14 Pharmacotherapies for Drug Addiction C. D. Gipson and P. W. Kalivas, 357, 
Chapter 15 Emerging Research towards the Understanding and Treatment of Autism Paul Wang, Rebecca Hammond, Friso Postma and Aileen Healy, 384, 
Chapter 16 Recent Chronology of Orexin Pharmacology and Its Potential as a Treatment for Primary Insomnia Christopher J. Winrow, Anthony L. Gotter, Paul J. Coleman, Richard Hargreaves and John J. Renger, 416, 
Section 4: Challenges and Future Directions in Drug Discovery for Psychiatric Disorders, 
Chapter 17 Crossing the Blood-brain Barrier – Methods for Evaluating CNS Exposure James A. Baker and Iain J. Martin, 445, 
Chapter 18 Medicinal Chemistry Challenges in CNS Drug Discovery Matilda Bingham and Zoran Rankovic, 465, 
Chapter 19 Multi-target Drug Discovery for Psychiatric Disorders Zoran Rankovic and Richard Morphy, 510, 
Chapter 20 The Possibilities and Limitations of Animal Models for Psychiatric Disorders Mark D. Tricklebank and Joseph P. Garner, 534, 
Chapter 21 Translational PET Imaging Research in Psychiatry Richard J. Hargreaves and Eugenii A. Rabiner, 558, 
Chapter 22 Future Drug Discovery for Psychiatric Disorders Darryle D. Schoepp and Richard J. Hargreaves, 574, 
Subject Index, 579,